{
    "2020-04-30": [
        [
            {
                "time": "",
                "original_text": "【药明康德|一季报点评】基本面强劲的CXO行业巨头【安信医药】",
                "features": {
                    "keywords": [
                        "药明康德",
                        "一季报",
                        "CXO",
                        "基本面强劲",
                        "安信医药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CXO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "被高瓴看好医药外包行业具备诞生世界龙头的潜力（附股）",
                "features": {
                    "keywords": [
                        "高瓴",
                        "医药外包",
                        "世界龙头",
                        "潜力"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "外包"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德（603259）：业绩维持稳健增长，长期发展动力充足【2020年一季报点评|西南医药朱国广/杜向阳团队】",
                "features": {
                    "keywords": [
                        "药明康德",
                        "业绩稳健增长",
                        "长期发展动力",
                        "一季报",
                        "西南医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国际药企受疫情影响暂缓研发计划 国内CRO公司复工复产或迎发展良机",
                "features": {
                    "keywords": [
                        "国际药企",
                        "疫情影响",
                        "研发计划",
                        "CRO",
                        "复工复产",
                        "发展良机"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}